Presidio Pharmaceuticals, Inc. to Present at the 45th Annual Meeting of the European Association for the Study of the Liver (EASL)
SAN FRANCISCO--(BUSINESS WIRE)--Apr 8, 2010 - Presidio Pharmaceuticals, Inc. announced today that Richard Colonno, PhD, Chief Scientific Officer, will present a summary of the profile of PPI-461, a potent and selective HCV NS5A inhibitor, recently designated as a clinical candidate by Presidio.
The presentation will occur during the parallel session: Hepatitis C: Drug Development at the International Liver Congress 2010, on April 15, 2010 at 5:30P (CET) in Hall E at the Reed Messe Wien Exhibition & Congress Center, in Vienna, Austria.
Presidio Pharmaceuticals, Inc. is a San Francisco-based specialty pharmaceutical company dedicated to the discovery and development of small-molecule antiviral therapeutics for novel and validated targets. For more information, please visit our website at: www.presidiopharma.com.
Contact: Presidio Pharmaceuticals, Inc.
Omar K. Haffar, PhD, 415-655-7561
Posted: April 2010